Stability of moxifloxacin injection in peritoneal dialysis solution bags (Dianeal PD1 1.36%® and Dianeal PD1 3.86%®)

Journal of Clinical Pharmacy and Therapeutics

Volumn 31, Issue 6, 2006, Pages 641-643

  Fernandez Varon E ^a,c   Marin P ^a   Espuny, A ^b   Villamayor, L ^a   Escudero, E ^a   Carceles C ^a  

^a UNIVERSITY OF MURCIA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^c UNIVERSITY OF MURCIA   (Spain)

Author keywords

Dialysis solutions; Moxifloxacin; Stability

Indexed keywords

CIPROFLOXACIN; DIALYSIS FLUID; DIANEAL; DIANEAL PD1; MOXIFLOXACIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; CLOUDINESS; COLOR; DEVICE; DRUG STABILITY; DRUG STORAGE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PERITONEAL DIALYSIS; PERITONEAL DIALYSIS SOLUTION BAG; PERITONITIS; PH MEASUREMENT; PRECIPITATION; SAMPLING; TEMPERATURE DEPENDENCE;

ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIALYSIS SOLUTIONS; DRUG STABILITY; INJECTIONS; PERITONEAL DIALYSIS; QUINOLINES; TEMPERATURE;

EID: 33751363183     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2006.00758.x     Document Type: Article

References (11)

1. Nakamoto H, Hashikita Y, Itabashi A, Kobayashi T, Suzuki H (2004) Changes in the organisms of resistant peritonitis in patients on continuous ambulatory peritoneal dialysis. Advances in peritoneal dialysis, 20, 52-57.
2. Piraino B, Bailie GR, Bernardini J et al. (2005) Peritoneal dialysed-related infections recommendations: 2005 update. Peritoneal Dialysis International, 25, 107-131.
3. Sharma RK, Kumar J, Gupta A, Gulati S (2003) Peritoneal infection in acute intermittent peritoneal dialysis. Renal Failure, 25, 975-980.
4. Stass H (1999) Absorption and bioavailability of moxifloxacin. Drugs, 58, 227-228.
5. Stass H, Kubitza D (1999) Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. Journal of Antimicrobial Chemotherapy, 43, 83-90.
6. Ball B (2000) Moxifloxacin (Avelox): an 8-methoxyquinolone antibacterial with enhanced potency. International Journal of Clinical Practice, 54, 329-332.
7. Blondeau JM, Hansen GT (2001) Moxifloxacin: a review of the microbiological, pharmacological, clinical and safety features. Expert Opinion on Pharmacotherapy, 2, 317-335.
8. Kane MP, Bailie GR, Moon DG, Siu I (1994) Stability of Ciprofloxacin injection in peritoneal dialysis solutions. American Journal of Hospital Pharmacy, 51, 373-377.
9. Mawhinney WM, Adair CG, Gorman SP, McClurg B (1992) Stability of Ciprofloxacin in peritoneal dialysis solution. American Journal of Hospital Pharmacy, 49, 2956-2959.
10. Battista C, Kane MP, Moon DG, Bailie GR (1995) Stability of ofloxacin in peritoneal dialysis solutions. Peritoneal Dialysis International, 15, 72-74.
11. Siefert HM, Kohlsdorfer C, Steinke W, Witt A (1999) Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: tissue distribution in male rats. Journal of Antimicrobial Chemotherapy, 43(Suppl. B), 61-67.